Keyphrases
Chronic Obstructive Pulmonary Disease
100%
Triple Therapy
100%
Long-acting muscarinic Antagonist
100%
Single-inhaler Triple Therapy
100%
Severe Exacerbations
75%
Moderate Exacerbations
75%
Randomized Controlled Trial
50%
Inhaled Corticosteroids
50%
Number-needed-to-treat
50%
Patient Phenotype
50%
Trial Registration
25%
Treatment Decisions
25%
High Incidence
25%
Clinical Trials
25%
Risk-benefit
25%
Funding Decisions
25%
Population Characteristics
25%
Pneumonia
25%
Adverse Events
25%
Long-acting β2-agonist
25%
Symptomatic Patients
25%
Patient-centered
25%
Absolute Benefit
25%
Patient Journey
25%
Specific Patient
25%
Design Characteristics
25%
Eosinophil Count
25%
Event-based
25%
Dual Therapy
25%
Ex-smokers
25%
Prospero
25%
CROSS Trial
25%
Medicine and Dentistry
Systematic Review
100%
Chronic Obstructive Pulmonary Disease
100%
Muscarinic Antagonist
100%
Randomized Controlled Trial
50%
Numbers Needed to Treat
50%
Arm
25%
Clinical Trial
25%
Base
25%
Adverse Event
25%
Comparison Trial
25%
Population and Population Related Phenomena
25%
Eosinophil
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Obstructive Lung Disease
100%
Muscarinic Receptor Blocking Agent
100%
Randomized Controlled Trial
50%
Number Needed to Treat
50%
Clinical Trial
25%
Base
25%
Adverse Event
25%
Comparison Trial
25%
Biochemistry, Genetics and Molecular Biology
Muscarinic Antagonist
100%
Randomized Controlled Trial
50%
Number Needed to Treat
50%
Clinical Trial
25%
Agonist
25%
Eosinophil Count
25%
Population and Population Related Phenomena
25%
Comparison Trial
25%